Member Info for Bckttsim

With buys outstripping sells big time, they are still trying to walk this down. Wonder if a couple of them put shorts on today. It would explain one sell and a drop , to lots of buys hardly any movement. If this takes off (which it could anytime) they could lose a packet. Must be some worried punters around.

On the rise NOW !

This is on the up big time. Don't let the tree shakes nerve you. £3 plus easy here

As I posted it bounced

Most of trades yesterday were above 160 MM's brought this down to balance books. How many sold and lost ?

MM's had no shares Bringing price down to get the ones back from yesterday. Doing a good job. This will not remain at this level .

Yes I would say ground breaking , no surgery !!!!!! Ground breaking Currently, pre-cervical cancer is treated by surgical removal of lesions however; PDS0101 could offer an effective non-surgical alternative. Results show that it primes and activates the body's defense mechanisms (T-cells) to recognize, target, and kill precancerous and cancerous cells that display HPV viral proteins, which are responsible for over 99% of cervical cancers. The patient population tested were those most likely to develop invasive cancer as they had little to no pre-treatment immune responses to HPV-16.

This beginning to get onto radar. Potential here is massive . Only ground breaking cancer treatment. Worth ...... Well billions .... Groundbreaking !

One things for certain, this is potentially huge.

The stake that NSCI has in PDS is 14.85% of PDS's share capital. NSCI also have warrants to buy more PDS shares. The warrants were valued at £100k in the EoY NSCI accounts. I have no idea what warrants there are, but let's say that, including the warrants, NSCI own 20% of PDS.

Taken from the PDS site Fourth Quarter 2014 PDS continues to make excellent progress with its ongoing phase 1 human clinical trial for PDS0101. Testing of the product in the final and highest dose cohort is in progress. PDS received its first institutional investment from NetScientific (AIM: NSCI), the biomedical and healthcare technology group in December 2014. In addition, Sir Richard Sykes accepted an invitation to join PDS’s board as Executive Chairman. Sir Richard was CEO and Chairman of GlaxoWellcome, and also Chairman of GSK. The following individuals also joined the board: Mr. De Lyle Bloomquist, President, Global Chemicals Business for Tata Chemicals Ltd. and President, CEO and Director of Tata Chemicals North America Inc.; Michael Boyce-Jacino, PhD, Executive Director of NetScientific and CEO of QLIDA; and Mr. Greg Freitag, General Counsel, Senior Vice President of Business Development, Ex-CFO and current Director of AxoGen, Inc.

Few sell 20% down May do the opposite tomorrow . Always look on the bright side of life lala lala lala lala lala

Value at this level . Going back to 70p min . I actually think it will hit £1 , excellent forward earnings forecast plus value .

No Stock Two very small trades moved price by 3% each time.

A few trades send this up quite rapidly. Seen it server all times in last few days.

Mr 2747 leaves Bought for 41.4p sold for 32.65p Top notch trader.

Operating income for 2015 estimated at E8.2 million Value of assets at end 2015 estimated at E126 million Taken from yesterday's RNS Generating CASH for reinvestment and a DIVIDEND !

As a result of these acquisitions the Gross Asset Value of the Company is now diversified as follows: Gross Asset Value ---------- ---------------------------------------------- EURm/% May 2015e 2014 2013 ---------- ------------ -------------------- ---------- Ukraine 32 26% 32 42% 40 100% ---------- ----- ----- ------------- ----- --- ----- Greece 16 13% 16 21% ---------- ----- ----- ------------- ----- --- ----- Romania 59 47% 29 37% ---------- ----- ----- ------------- ----- --- ----- Bulgaria 19 15% 0% ---------- ----- ----- ------------- ----- --- ----- Total 126 100% 77 100% 40 100% ---------- ----- ----- ------------- ----- --- ----- Furthermore, the annualized Net Operating Income, considering also the newly acquired assets is estimated as follows: Annualized Net Operating Income ---------- ------------------------------------------ EURm May 2015e 2014 2013 ---------- -------------- ------------- ----------- Ukraine 2,3 28% 2,4 40% 2,7 100% ---------- ------ ------ ----- ------ ---- ----- Greece 1,5 18% 1,5 24% ---------- ------ ------ ----- ------ ---- ----- Romania 3,7 46% 2,1 36% ---------- ------ ------ ----- ------ ---- ----- Bulgaria 0,7 9% 0% ---------- ------ ------ ----- ------ ---- ----- Total 8,2 100% 6,0 100% 2,7 100% ---------- ------ ------ ----- ------ ---- ----- As such, our focus in 2015 is a) to improve even further the Company's operating results, b) leading to a dividend distribution for the first time in its history in 2016, while at the same time to attract more like minded investors and grow the Company's balance sheet with both new capital and assets in other countries in the South East Europe region, while safeguarding our position and income in Ukraine.

GREXIT would harm everybody and us in the UK and not just these guys. Plus the fact only one acquisition in Greece . This company's performance is exceptional for AIM , it is very undervalued.

This surely has to re-rate from here. Not much interest , however what interest we do get sends the price flying. If you had any sense you would realise this and hold onto your shares, the price would then gain momentum and could have quite easily doubled today. Up 40% plus at one point. Well shrewd people may have noticed this because with next to no shares available with a little interest the same will happen for sure . I believe this is heading towards the £1 plus mark over the next few sessions . It's what it's worth.